ViaCyte

BioTech/Drugs - San Diego, CA, US

ViaCyte Employees
Craig Mcgreevy

director of engineering and device manufacturing

Contact Craig Mcgreevy

Jay Sorensen

Senior Director, Manufacturing

Contact Jay Sorensen

Alan Agulnick

director, cell engineering

Contact Alan Agulnick

Lori Hays

Director of Regulatory Affairs

Contact Lori Hays

Zeny Ortega

Director of QA and Compliance

Contact Zeny Ortega

Dan Pontoriero

Director of Clinical Data Management

Contact Dan Pontoriero

Mark Zimmerman

Senior Vice President of Business Development and Operations

Contact Mark Zimmerman

View All ViaCyte Employees Contact All ViaCyte Employees
ViaCyte Senior Management
Kevin 'D''Amour'

Vice President, Research and CSO

Contact Kevin 'D''Amour'

Steven White

Chief Technology Officer

Contact Steven White

Michael Yang

President and Chief Executive Officer

Contact Michael Yang

Alyssa Levin

Chief Financial Officer

Contact Alyssa Levin

View All ViaCyte Employees Contact All ViaCyte Employees
ViaCyte Details

About ViaCyte ViaCyte is a privately held regenerative medicine company developing novel cell replacement therapies as potential long-term diabetes treatments to achieve glucose control targets and reduce the risk of hypoglycemia and diabetes-related complications. ViaCyte's product candidates are based on directed differentiation of pluripotent stem cells into PEC-01 pancreatic islet progenitor cells, which are then implanted in durable and retrievable cell delivery devices. ViaCyte demonstrated that when effectively engrafted, PEC-01 cells can mature into glucose-responsive insulin producing cells in patients with type 1 diabetes. To accelerate and expand its efforts, ViaCyte has established collaborative partnerships with leading companies including CRISPR Therapeutics and W.L. Gore & Associates.About ViaCyte's Pipeline The PEC-Direct product candidate, currently being evaluated in the clinic, delivers ViaCyte's PEC-01 cells (pancreatic islet progenitor cells) in a non-immunoprotective device and is being developed for type 1 diabetes patients who have hypoglycemia unawareness, extreme glycemic lability, and/or recurrent severe hypoglycemic episodes. The PEC-Encap (also known as VC-01) product candidate, also undergoing clinical evaluation, delivers the same pancreatic islet progenitor cells but in an immunoprotective device. PEC-Encap is being developed for all patients with type 1 diabetes. In collaboration with CRISPR Therapeutics, ViaCyte is developing immune-evasive stem cell lines from its proprietary CyT49 cell line. These immune-evasive stem cell lines, which are being used in the PEC-QT program, have the potential to further broaden the availability of cell therapy for all patients with insulin-requiring diabetes, type 1 and type 2. In addition, a pluripotent, immune evasive cell line has the potential to be used to produce any cell in the body, thus enabling many other potential indications.

ViaCyte logo, ViaCyte contact details
Website: viacyte.com
Employees: 100 - 249
HQ: 858-207-0500
Location: San Diego, CA, US
Revenue: 20 - 50 Million
B2B Biotechnology Healthcare Pharmaceuticals Biotech BioTech/Drugs Commercial Physical Research
ViaCyte Technologies
Email Providers

Outlook

CMS

WP Engine

Other

Microsoft Office 365

Hosting

Google Cloud Hosting

Recruitment

ADP

View All Technologies Used At ViaCyte

Contacting ViaCyte: Connect with Executives and Employees

Get in Touch with ViaCyte Executives and Employees

Connecting with ViaCyte's Executives and Workforce

Accessing Contact Information for ViaCyte Executives

Connecting with ViaCyte: Reach Out to Their Team

Discover How to Contact ViaCyte Executives and Staff

Looking to connect with ViaCyte executives or employees?

Seeking to Get in Touch with ViaCyte Executives or Staff?

Want to Reach Out to ViaCyte Executives or Team Members?

In Search of Contact Details for ViaCyte Professionals?

Connecting with ViaCyte: Contacting Executives and Staff

Browse companies
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z